Advanced Glucose Control References –

1. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008 May;57(5):712-17. [PMID: 18442638]

2. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008 Jul;93(7):2559-65. [PMID: 18397984]
3. Li Z, Geng YN, Jiang JD, et al. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med. 2014;2014:289264. [PMID: 24669227]

4. Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006 Aug;55(8):2256-64. [PMID: 16873688]

5. Wang Q, Zhang M, Liang B, et al. Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2. PLoS One. 2011;6(9):e25436. Epub 2011 Sep 27. [PMID: 21980456]

6. Zhang M, Wang CM, Li J, et al. Berberine protects against palmitate-induced endothelial dysfunction: involvements of upregulation of AMPK and eNOS and downregulation of NOX4. Mediators Inflamm. 2013;2013:260464. [PMID: 24385682]

7. Yang J, Yin J, Gao H, et al. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evid Based Complement Alternat Med. 2012;2012:363845. [PMID: 22474499]

8. Zhou J, Zhou S. Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes. Eur J Pharmacol. 2010 Dec 15;649(1-3):390-97. [PMID: 20868663]

9. Zhou LB, Chen MD, Wang X, et al. Effect of berberine on the differentiation of adipocyte [in Chinese]. Zhonghua Yi Xue Za Zhi. 2003 Feb 25;83(4):338-40. [PMID: 12812656]

10. Liu Y, Lou SY, He YM. Effects of berberine on cell proliferation, peroxisome proliferation activated receptor gamma, CAAT/enhancer binding protein mRNA and protein expression in 3T3-L1 pre-adipocytes [in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Nov;28(11):1005-09. [PMID: 19213344]

11. Li GS, Liu XH, Zhu H, et al. Berberine-improved visceral white adipose tissue insulin resistance associated with altered sterol regulatory element-binding proteins, liver x receptors, and peroxisome proliferator-activated receptors transcriptional programs in diabetic hamsters. Biol Pharm Bull. 2011;34(5):644- 54. [PMID: 21532151]

12. Golbidi S, Badran M, Laher I. Diabetes and alpha lipoic acid. Front Pharmacol. 2011;2:69. [PMID: 22125537]

13. Hahm JR, Noh HS, Ha JH, et al. Alpha-lipoic acid attenuates adipocyte differentiation and lipid accumulation in 3T3-L1 cells via AMPK-dependent autophagy. Life Sci. 2014 Apr 1;100(2):125-32. Epub 2014 Feb 14. [PMID: 24530288]

14. Diesel B, Kulhanek-Heinze S, Höltje M, et al. Alpha-lipoic acid as a directly binding activator of the insulin receptor: protection from hepatocyte apoptosis. Biochemistry. 2007 Feb 27;46(8):2146-55. [PMID: 17274632]

15. Konrad D, Somwar R, Sweeney G, et al. The antihyperglycemic drug alphalipoic acid stimulates glucose uptake via both GLUT4 translocation and GLUT4 activation: potential role of p38 mitogen-activated protein kinase in GLUT4 activation. Diabetes. 2001 Jun;50(6):1464-71. [PMID: 11375349]